Login to Your Account

CRL wants Acelrx data on dose, text to prevent device flubs

By Randy Osborne
Staff Writer

Thursday, October 12, 2017

Acelrx Pharmaceuticals Inc. CEO Vincent Angotti said he was “hesitant to put a timeline on this until we get further clarification from the FDA” regarding what’s required to satisfy the agency’s issues raised in a CRL related to its NDA for 30-mg sublingual tablet Dsuvia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription